Long-term outcomes of peripheral atherectomy for femoropopliteal endovascular interventions.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
03 Apr 2023
Historique:
pmc-release: 03 04 2024
medline: 10 4 2023
pubmed: 15 11 2022
entrez: 14 11 2022
Statut: epublish

Résumé

The use of atherectomy during peripheral endovascular interventions (PVI) has increased dramatically, but data regarding its safety and effectiveness are lacking.  Aims: This study sought to determine the long-term safety of atherectomy in contemporary practice.  Methods: Medicare fee-for-service beneficiaries who underwent femoropopliteal artery PVI from 2015-2018 were identified in a 100% sample of inpatient, outpatient, and carrier file data using procedural claims codes. The primary exposure was the use of atherectomy. Inverse probability of treatment weighting was used to adjust for measured differences in patient populations. Kaplan-Meier methods and multivariable Cox proportional hazards regression were used to compare outcomes.  Results: Among 168,553 patients who underwent PVI, 59,142 (35.1%) underwent atherectomy. The mean patient age was 77.0±7.6 years, 44.9% were female, 81.9% were white, and 46.7% had chronic limb-threatening ischaemia. Over a median follow-up time of 993 days (interquartile range 319-1,377 days), atherectomy use was associated with no difference in the risk of either the composite endpoint of death and amputation (adjusted hazard ratio [aHR] 0.99, 95% confidence interval [CI]: 0.97-1.01; p=0.19) or of major adverse limb events (aHR 1.02, 95% CI: 0.99-1.05; p=0.26). Patients who underwent atherectomy had a modest reduction in the risk of subsequently undergoing amputation or surgical revascularisation (aHR 0.92, 95% CI: 0.90-0.94; p<0.01) but an increase in the risk of undergoing a subsequent PVI (aHR 1.19, 95% CI: 1.16-1.21; p<0.01). The use of atherectomy during femoropopliteal artery PVI was not associated with an increase in the risk of long-term adverse safety outcomes among patients with peripheral artery disease.

Sections du résumé

BACKGROUND BACKGROUND
The use of atherectomy during peripheral endovascular interventions (PVI) has increased dramatically, but data regarding its safety and effectiveness are lacking.  Aims: This study sought to determine the long-term safety of atherectomy in contemporary practice.  Methods: Medicare fee-for-service beneficiaries who underwent femoropopliteal artery PVI from 2015-2018 were identified in a 100% sample of inpatient, outpatient, and carrier file data using procedural claims codes. The primary exposure was the use of atherectomy. Inverse probability of treatment weighting was used to adjust for measured differences in patient populations. Kaplan-Meier methods and multivariable Cox proportional hazards regression were used to compare outcomes.  Results: Among 168,553 patients who underwent PVI, 59,142 (35.1%) underwent atherectomy. The mean patient age was 77.0±7.6 years, 44.9% were female, 81.9% were white, and 46.7% had chronic limb-threatening ischaemia. Over a median follow-up time of 993 days (interquartile range 319-1,377 days), atherectomy use was associated with no difference in the risk of either the composite endpoint of death and amputation (adjusted hazard ratio [aHR] 0.99, 95% confidence interval [CI]: 0.97-1.01; p=0.19) or of major adverse limb events (aHR 1.02, 95% CI: 0.99-1.05; p=0.26). Patients who underwent atherectomy had a modest reduction in the risk of subsequently undergoing amputation or surgical revascularisation (aHR 0.92, 95% CI: 0.90-0.94; p<0.01) but an increase in the risk of undergoing a subsequent PVI (aHR 1.19, 95% CI: 1.16-1.21; p<0.01).
CONCLUSIONS CONCLUSIONS
The use of atherectomy during femoropopliteal artery PVI was not associated with an increase in the risk of long-term adverse safety outcomes among patients with peripheral artery disease.

Identifiants

pubmed: 36373386
pii: EIJ-D-22-00609
doi: 10.4244/EIJ-D-22-00609
pmc: PMC10078823
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1378-e1387

Références

Fed Regist. 2010 Nov 29;75(228):73169-860
pubmed: 21121181
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Fed Regist. 2007 May 11;72(91):26869-7029
pubmed: 17520779
J Vasc Surg. 2021 May;73(5):1693-1700.e3
pubmed: 33253869
J Vasc Surg. 2021 Aug;74(2):499-504
pubmed: 33548437
Quant Imaging Med Surg. 2020 Jan;10(1):283-293
pubmed: 31956549
J Vasc Surg. 2018 Dec;68(6):1806-1816
pubmed: 29937287
J Vasc Surg. 2017 Feb;65(2):495-500
pubmed: 27986487
J Am Coll Cardiol. 2013 Dec 3;62(22):2147-8
pubmed: 23954334
J Am Coll Cardiol. 2015 Mar 10;65(9):920-7
pubmed: 25744009
Cochrane Database Syst Rev. 2014 Mar 17;(3):CD006680
pubmed: 24638972
Cardiovasc Intervent Radiol. 2014 Aug;37(4):898-907
pubmed: 24806955
Eur Radiol. 2022 Mar;32(3):1697-1708
pubmed: 34647176
J Am Heart Assoc. 2019 Jun 18;8(12):e012081
pubmed: 31165658
EuroIntervention. 2022 Aug 05;18(5):e432-e442
pubmed: 35389346
Lancet. 2013 Oct 19;382(9901):1329-40
pubmed: 23915883
Circ Cardiovasc Interv. 2019 Sep;12(9):e008097
pubmed: 31495219
Ann Vasc Surg. 2022 Sep;85:146-155
pubmed: 35271966

Auteurs

Anna K Krawisz (AK)

Department of Medicine, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Aishwarya Raja (A)

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

W Schuyler Jones (WS)

Division of Cardiology, Department of Medicine, Duke University Health System, Durham, NC, USA.

Peter Schneider (P)

Division of Vascular and Endovascular Surgery, University of California San Francisco, San Francisco, CA, USA.

Changyu Shen (C)

Department of Medicine, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Marc Schermerhorn (M)

Division of Vascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Eric A Secemsky (EA)

Department of Medicine, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH